| Dr Sean Francis Pinard, OD | |
|
124 E Main St Ste 1, Newport, VT 05855-5561 | |
| (802) 334-2772 | |
| (802) 334-5667 |
| Full Name | Dr Sean Francis Pinard |
|---|---|
| Gender | Male |
| Speciality | Optometry |
| Experience | 7 Years |
| Location | 124 E Main St Ste 1, Newport, Vermont |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1891224069 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 0129559 (Vermont) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Premier Vision Partners | 1850789553 | 2 |
| Winder Eye Care Center | 1153312871 | 4 |
News Archive
A case-control study published today in the open access journal BMC Cancer observed that daily use of selective COX-2 inhibitors, including celecoxib (Celebrex) and rofecoxib (Vioxx), was associated with a 71% reduction in the risk of breast cancer.
On November 20 at the American Society of Nephrology 43rd Annual Meeting, interim results presented from an ongoing, randomized prospective study conducted independently by James A. Tumlin, MD, at the University of Tennessee College of Medicine Chattanooga indicated that 9 of 15 patients (60%) with advanced diabetic nephropathy who are currently enrolled in the study and have completed or are still undergoing a six month course of treatment with H.P. Acthar ® Gel have exhibited a clinically significant decrease in proteinuria and achieved stabilized renal function.
Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today announced positive results from its Phase 2 clinical trial with DSC127 in patients with diabetic foot ulcers, including meeting the trial's primary endpoint, the proportion of study ulcers healed by 12 weeks as defined by 100% epithelialized with no drainage, as well as all secondary endpoints measured at this time.
Over the last three decades there has been a rise in the number of twins born in the U.S. Mostly this is the result of test-tube babies and women waiting to have children until their 30s, when the chances of twins increase. In 2009, 1 in every 30 babies born in the U.S. was a twin, an astounding increase over the 1 in 53 rate in 1980, according to a government report issued Wednesday.
› Verified 8 days ago
| Provider Name | Winder Eye Care Center |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1154349041 PECOS PAC ID: 1153312871 Enrollment ID: O20040521000074 |
News Archive
A case-control study published today in the open access journal BMC Cancer observed that daily use of selective COX-2 inhibitors, including celecoxib (Celebrex) and rofecoxib (Vioxx), was associated with a 71% reduction in the risk of breast cancer.
On November 20 at the American Society of Nephrology 43rd Annual Meeting, interim results presented from an ongoing, randomized prospective study conducted independently by James A. Tumlin, MD, at the University of Tennessee College of Medicine Chattanooga indicated that 9 of 15 patients (60%) with advanced diabetic nephropathy who are currently enrolled in the study and have completed or are still undergoing a six month course of treatment with H.P. Acthar ® Gel have exhibited a clinically significant decrease in proteinuria and achieved stabilized renal function.
Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today announced positive results from its Phase 2 clinical trial with DSC127 in patients with diabetic foot ulcers, including meeting the trial's primary endpoint, the proportion of study ulcers healed by 12 weeks as defined by 100% epithelialized with no drainage, as well as all secondary endpoints measured at this time.
Over the last three decades there has been a rise in the number of twins born in the U.S. Mostly this is the result of test-tube babies and women waiting to have children until their 30s, when the chances of twins increase. In 2009, 1 in every 30 babies born in the U.S. was a twin, an astounding increase over the 1 in 53 rate in 1980, according to a government report issued Wednesday.
› Verified 8 days ago
| Provider Name | Premier Vision Partners |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1376213165 PECOS PAC ID: 1850789553 Enrollment ID: O20211029001277 |
News Archive
A case-control study published today in the open access journal BMC Cancer observed that daily use of selective COX-2 inhibitors, including celecoxib (Celebrex) and rofecoxib (Vioxx), was associated with a 71% reduction in the risk of breast cancer.
On November 20 at the American Society of Nephrology 43rd Annual Meeting, interim results presented from an ongoing, randomized prospective study conducted independently by James A. Tumlin, MD, at the University of Tennessee College of Medicine Chattanooga indicated that 9 of 15 patients (60%) with advanced diabetic nephropathy who are currently enrolled in the study and have completed or are still undergoing a six month course of treatment with H.P. Acthar ® Gel have exhibited a clinically significant decrease in proteinuria and achieved stabilized renal function.
Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today announced positive results from its Phase 2 clinical trial with DSC127 in patients with diabetic foot ulcers, including meeting the trial's primary endpoint, the proportion of study ulcers healed by 12 weeks as defined by 100% epithelialized with no drainage, as well as all secondary endpoints measured at this time.
Over the last three decades there has been a rise in the number of twins born in the U.S. Mostly this is the result of test-tube babies and women waiting to have children until their 30s, when the chances of twins increase. In 2009, 1 in every 30 babies born in the U.S. was a twin, an astounding increase over the 1 in 53 rate in 1980, according to a government report issued Wednesday.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Sean Francis Pinard, OD 124 E Main St Ste 1, Newport, VT 05855-5561 Ph: (802) 334-2772 | Dr Sean Francis Pinard, OD 124 E Main St Ste 1, Newport, VT 05855-5561 Ph: (802) 334-2772 |
News Archive
A case-control study published today in the open access journal BMC Cancer observed that daily use of selective COX-2 inhibitors, including celecoxib (Celebrex) and rofecoxib (Vioxx), was associated with a 71% reduction in the risk of breast cancer.
On November 20 at the American Society of Nephrology 43rd Annual Meeting, interim results presented from an ongoing, randomized prospective study conducted independently by James A. Tumlin, MD, at the University of Tennessee College of Medicine Chattanooga indicated that 9 of 15 patients (60%) with advanced diabetic nephropathy who are currently enrolled in the study and have completed or are still undergoing a six month course of treatment with H.P. Acthar ® Gel have exhibited a clinically significant decrease in proteinuria and achieved stabilized renal function.
Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today announced positive results from its Phase 2 clinical trial with DSC127 in patients with diabetic foot ulcers, including meeting the trial's primary endpoint, the proportion of study ulcers healed by 12 weeks as defined by 100% epithelialized with no drainage, as well as all secondary endpoints measured at this time.
Over the last three decades there has been a rise in the number of twins born in the U.S. Mostly this is the result of test-tube babies and women waiting to have children until their 30s, when the chances of twins increase. In 2009, 1 in every 30 babies born in the U.S. was a twin, an astounding increase over the 1 in 53 rate in 1980, according to a government report issued Wednesday.
› Verified 8 days ago
Francis L Pinard Od Pc Optometrist Medicare: Medicare Enrolled Practice Location: 124 East Main Street, Suite #1, Newport, VT 05855 Phone: 802-334-2772 Fax: 802-334-5667 | |
Francis L Pinard, O.D. Optometrist Medicare: May Accept Medicare Assignments Practice Location: 124 E Main St, Ste #1, Newport, VT 05855 Phone: 802-334-2772 Fax: 802-334-5667 | |
Caroline Sutton, OD Optometrist Medicare: Medicare Enrolled Practice Location: 124 E Main St, Newport, VT 05855 Phone: 802-334-2772 | |
Dr. Marika Parenteau, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 5452 Us Route 5, Ste H, Newport, VT 05855 Phone: 802-334-1515 Fax: 802-334-2935 |